Integrated support for a small biotech

Prime supported a small biotech on launch and pre-launch. This was initially to support scientific communication planning and develop value dossiers to help support US payer engagement, but in discussions it soon became evident that interpreting the patient benefit and communicating the value was another critical area where Prime could support.

Challenge

Our client needed advice on how to interpret and communicate the patient benefit to support both regulatory and market access discussions.

Our solution

An integrated team of scientific, HEOR, strategy and market access experts supported the tactical execution of evidence generation, including the development of a budget impact model and an AMCP dossier. Additionally, to augment the value story with a patient-centric perspective, a patient preference study was commissioned to measure the relative importance of different treatment factors.

This led to significant progress in product development and the delivery of communications for both scientific and payor audiences. The program of work provided several synergies for the client through the integration of services from the teams at Prime. This iterative consultancy advice has resulted in new data to enhance the evidence base.